Search clinical trials for: anti-pd-1
Total 130912 results
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Daniela Matei, MDMerck Sharp & Dohme LLC; Hoosier Cancer Research NetworkCompletedEndometrial Cancer | Endometrial AdenocarcinomaUnited States
-
Zhejiang Cancer HospitalNot yet recruitingGastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and SurgeryChina
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin Pharma, Inc.CompletedIdiopathic Parkinson's DiseaseUnited States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin Pharma, Inc.CompletedIdiopathic Parkinson's DiseaseUnited States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
-
Shanghai Chest HospitalNot yet recruitingEsophageal CancerChina
-
University of Colorado, DenverNational Cancer Institute (NCI); Cancer League of ColoradoWithdrawnColorectal Cancer | Microsatellite Instability High | Mismatch Repair DeficiencyUnited States
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingNasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell CarcinomaChina
-
Shanghai Zhongshan HospitalRecruiting
-
Beijing Friendship HospitalCompletedCamrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.Biliary Tract Cancer | Capecitabine | Targeted Molecular Therapy | Anti-PD-1 TherapyChina
-
Chinese PLA General HospitalRecruitingHodgkin Lymphoma | Anti-PD-1 Antibody ResistantChina
-
Zhongnan HospitalRecruitingHepatocellular Carcinoma; Targeted Therapy; Progression-free SurvivalChina
-
Capital Medical UniversityDuke UniversityCompleted
-
Capital Medical UniversityDuke University; Geneplus-Beijing Co. Ltd.CompletedNeoplasms | Lung CancerChina
-
Sun Yat-sen UniversityRecruitingImmunotherapy | DMMR Colorectal Cancer | Anti PD-1China
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Guohui LiRecruitingPD-1 | Immune Related Adverse EventsChina
-
PDC*line Pharma SASActive, not recruitingSafety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLCNon Small Cell Lung CancerBelgium, France, Netherlands, Germany, Poland
-
Centre Leon BerardNETRIS PharmaRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsFrance
-
Huabo Biopharm Co., Ltd.Recruiting
-
CureVacSyneos Health; Cromos Pharma LLCActive, not recruitingCarcinoma, Adenoid Cystic | Melanoma (Skin) | Squamous Cell Carcinoma of the Skin | Carcinoma, Squamous Cell of Head and NeckSpain, France, Austria, Germany, Russian Federation
-
Shanghai Jiao Tong University School of MedicineRecruitingOral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy | Anti-VEGFRChina
-
Istari Oncology, Inc.Active, not recruiting
-
Waterstone Hanxbio Pty LtdCompletedAdvanced Solid TumorAustralia
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical University; Sichuan Cancer Hospital... and other collaboratorsRecruitingRectal Cancer | Radiotherapy | Anti-PD-1 Antibody | MSI-H | Mmr DeficiencyChina
-
Bristol-Myers SquibbActive, not recruitingNeoplasms by SiteUnited States, Australia, Denmark, France, Switzerland, Austria, Canada, Germany, Japan, Netherlands, Norway, Spain, United Kingdom, Finland, Italy
-
PfizerActive, not recruitingRenal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma CancerUnited States, Taiwan, Korea, Republic of, Australia, Slovakia
-
Ascendis Pharma Oncology Division A/SRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...United States, Australia, Korea, Republic of
-
Third Military Medical UniversityRecruitingSmall Cell Lung Cancer | Lung Cancer | SCLC, Extensive StageChina
-
AkesoCompletedHCC | Lung Cancer | Solid TumorChina
-
Tang-Du HospitalRecruitingNSCLC Stage IV | OligometastasisChina
-
OncoC4, Inc.Avance Clinical; OncoC4 AU Pty LtdRecruitingMelanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Fallopian Tube Cancer | Non Small Cell Lung Cancer | Bile Duct Cancer | Bladder Cancer | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Primary Peritoneal... and other conditionsAustralia
-
Bristol-Myers SquibbCompletedNeoplasms by SiteUnited States
-
The First Hospital of Jilin UniversityNot yet recruitingLocally Advanced Rectal Cancer | Anti-PD-1 | Total Neoadjuvant TreatmentChina
-
Merck Sharp & Dohme LLCArray BioPharmaCompletedMetastatic Colorectal CancerUnited States, Canada
-
Peking Union Medical College HospitalRecruitingAnlotinib | Anti-PD-1 Antibody | Advanced Pancreatic CancerChina
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Immunotherapy | Anti-PD-1 Antibody | Persistent Advanced Cervical CarcinomaChina
-
Agenus Inc.CompletedCervical Cancer | Advanced CancerFrance, United States, Belgium, Australia, Spain, Estonia, Brazil, Chile, Poland
-
Shanghai International Medical CenterUnknownAdvanced Solid Tumor | PD-1 Antibody | CAR-T CellsChina
-
Agenus Inc.Withdrawn
-
AkesoAkeso Pharmaceuticals, Inc.CompletedHepatocellular CarcinomaChina
-
AkesoAkeso Pharmaceuticals, Inc.TerminatedPeripheral T-cell LymphomaChina
-
Centre hospitalier de l'Université de Montréal...CompletedNon-small Cell Lung Cancer Metastatic | Cryotherapy EffectCanada
-
Fukushima Medical UniversityKanagawa Cancer CenterUnknown
-
Beijing Tongren HospitalNot yet recruitingExtranodal NK/T-cell Lymphoma, Nasal Type
-
Coherus Biosciences, Inc.Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.Active, not recruitingHepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid TumorUnited States
-
Symphogen A/SCompletedLymphoma | Solid Tumor | Metastatic CancerCanada, United States
-
Symphogen A/SActive, not recruitingSym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor MalignanciesSolid Tumor | Metastatic CancerUnited States, Canada
-
Shanghai Zhongshan HospitalRecruitingHepatocellular CarcinomaChina
-
Ningbo Cancer HospitalUnknownAdvanced Malignancies | PD-1 Antibody | CAR-T CellsChina